BrainsWay (NASDAQ:BWAY – Get Rating) had its price objective lowered by Northland Securities from $15.00 to $5.00 in a research note released on Thursday morning, The Fly reports. Northland Securities currently has an outperform rating on the stock.
Several other research analysts also recently weighed in on the stock. HC Wainwright increased their price target on shares of BrainsWay from $15.00 to $16.00 and gave the stock a buy rating in a research report on Monday, August 22nd. Raymond James decreased their price objective on shares of BrainsWay from $10.00 to $8.00 and set an outperform rating on the stock in a research report on Thursday, August 11th.
BrainsWay Trading Up 1.3 %
BWAY opened at $2.03 on Thursday. BrainsWay has a 1-year low of $1.90 and a 1-year high of $9.18. The company has a market capitalization of $33.45 million, a PE ratio of -6.33 and a beta of 1.42. The firm’s 50 day simple moving average is $3.49 and its two-hundred day simple moving average is $4.85.
Institutional Trading of BrainsWay
BrainsWay Company Profile
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on BrainsWay (BWAY)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.